By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NovoCure Ltd. 

Bridgeport  Connecticut  06610  U.S.A.
Phone: n/a Fax:


Medical Device

Company News
NovoCure To Present Three Abstracts On Tumor Treating Fields And Pancreatic Cancer At The European Society For Medical Oncology 19th World Congress On Gastrointestinal Cancer 6/28/2017 10:31:05 AM
NovoCure Release: First Patient Enrolled In RTOG Trial Of Optune Together With Bevacizumab For Patients With Bevacizumab-Refractory Recurrent Glioblastoma 6/8/2017 7:07:18 AM
NovoCure Release: Health Care Service Corporation Issues Positive Coverage Decision For Optune 6/5/2017 7:30:51 AM
NovoCure Receives Humanitarian Use Device Designation For Treatment Of Pleural Mesothelioma 5/15/2017 6:08:43 AM
Martin J. Madden Joins NovoCure Board Of Directors 5/11/2017 8:23:02 AM
NovoCure Release: Combination Of Optune With Standard Of Care Chemotherapy, Temozolomide, Delayed Decline In Several Health-Related Quality Of Life Scales Compared To Temozolomide Alone For Newly Diagnosed Glioblastoma Patients 5/8/2017 6:15:26 AM
NovoCure Announces Opening Of Two Pilot Trials To Evaluate The Use Of TTFields For Pediatric Gliomas 5/4/2017 6:28:42 AM
NovoCure Reports First Quarter 2017 Financial Results And Provides Company Update 4/27/2017 5:39:43 AM
NovoCure Announces Four Presentations On Tumor Treating Fields At American Academy of Neurology Annual Meeting In Boston 4/19/2017 6:15:35 AM
NovoCure Release: CNS Oncology Publishes Data Suggesting Survival Benefit Of Optune In Combination With Second Line Chemotherapies After Glioblastoma Recurrence 4/17/2017 9:29:00 AM